prophylaxis of Bleeding (DBCOND0020314)

Identifiers

Synonyms

Prophylaxis of bleeding episodes

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Albutrepenonacog alfa	A recombinant Factor IX fused to recombinant human albumin used to treat hemophilia B.	Coagulation factor Xtarget Coagulation factor VIIIenzyme
Antihemophilic factor (recombinant), PEGylated	For the management of hemophilia A (congenital factor VIII deficiency) [FDA label], . This medication is a human antihemophilic factor indicated in adolescent and adult patients (12 years and older)...	von Willebrand factortarget von Willebrand factorcarrier
Antihemophilic factor, human recombinant	A form of recombinant coagulation Factor VIII used to treat hemophilia A, von Willebrand disease, and Factor XIII deficiency.	Coagulation factor Xtarget Phytanoyl-CoA dioxygenase, peroxisomaltarget Coagulation factor IXtarget Asialoglycoprotein receptor 2target Endoplasmic reticulum chaperone BiPtarget Calreticulintarget Calnexintarget Protein ERGIC-53target Prolow-density lipoprotein receptor-related protein 1target Multiple coagulation factor deficiency protein 2target von Willebrand factortarget Prothrombinenzyme Vitamin K-dependent protein Cenzyme
Catridecacog	A recombinant FXIII subunit‐A molecule evaluated for clotting factor replacement therapy in congenital FXIII deficiency.	Coagulation factor XIII B chaintarget
Coagulation Factor IX (Recombinant)	A form of recombinant human coagulation Factor IX used to treat hemophilia B.	Coagulation factor Xtarget Coagulation factor XItarget Coagulation factor VIIItarget Prothrombintarget Coagulation factor VIItarget Vitamin K-dependent gamma-carboxylasetarget Prolow-density lipoprotein receptor-related protein 1target
Coagulation factor X human	A coagulation factor used to treat Factor X deficiency to control bleeding.	No drug targets
Desmopressin	A synthetic analog of vasopressin used to reduce renal excretion of water in central diabetes insipidus and nocturia.	Vasopressin V1a receptortarget Vasopressin V1b receptortarget Vasopressin V2 receptortarget Prostaglandin G/H synthase 1enzyme Prostaglandin G/H synthase 2enzyme Oxytocin receptortarget
Efanesoctocog alfa	A recombinant DNA-derived, Factor VIII concentrate indicated for routine prophylaxis, on-demand treatment and control of bleeding episodes, and perioperative management of bleeding in patients with hemophilia A.	Low-density lipoprotein receptor-related protein 2target Basement membrane-specific heparan sulfate proteoglycan core proteintarget Coagulation factor IXtarget Coagulation factor Xtarget
Efmoroctocog alfa	A recombinant Factor VIII used to treat and prevent bleeding in hemophilia A.	von Willebrand factortarget
Factor IX Complex (Human)	A Factor IX complex used to prevent and treat bleeding episodes in hemophilia B or vitamin K antagonist therapy.	No drug targets
Lonoctocog alfa	A recombinant Factor VIII used to treat hemophilia A to control bleeding.	Coagulation factor Xtarget Phytanoyl-CoA dioxygenase, peroxisomaltarget Coagulation factor IXtarget Asialoglycoprotein receptor 2target Endoplasmic reticulum chaperone BiPtarget Calreticulintarget Calnexintarget Protein ERGIC-53target Prolow-density lipoprotein receptor-related protein 1target Multiple coagulation factor deficiency protein 2target von Willebrand factortarget Prothrombinenzyme Vitamin K-dependent protein Cenzyme
Turoctocog alfa	An antihemorrhagic agent used for the treatment and prophylaxis of bleeding in patients of all ages with haemophilia A (congenital factor VIII deficiency).	Coagulation factor IXtarget Coagulation factor Xtarget Prothrombintarget
Von Willebrand factor human	A blood clotting factor used to manage bleeding episodes in von Willebrand disease and hemophilia A.	Coagulation factor VIIItarget Collagen alpha-1(I) chaintarget A disintegrin and metalloproteinase with thrombospondin motifs 13enzyme Asialoglycoprotein receptor 1target Prolow-density lipoprotein receptor-related protein 1target

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT05036278	Prophylaxis Regimen for Hemophilia A Patients	Antihemophilic factor (recombinant), PEGylated Damoctocog alfa pegol	treatment	4	active_not_recruiting
NCT05147662	A Study to Learn How Safe the Study Treatment BAY94-9027 is and How it Affects the Body in Previously Treated Children Aged 7 to Less Than 12 Years With Severe Hemophilia A, a Genetic Bleeding Disorder That is Caused by the Lack of a Protein Called Clotting Factor 8 (FVIII) in the Blood	Antihemophilic factor (recombinant), PEGylated Damoctocog alfa pegol	treatment	3	active_not_recruiting
NCT06222697	A Study to Learn More About the Safety of Damoctocog-alfa-pegol When Used in Routine Medical Care in Korean Participants With Hemophilia A	Antihemophilic factor (recombinant), PEGylated Damoctocog alfa pegol	Not Available	Not Available	recruiting
NCT05643560	An Observational Study Called JOIHA to Learn More About How Well the Treatment With Jivi Works to Prevent Problems With Joints in Adults With Hemophilia A	Antihemophilic factor (recombinant), PEGylated Damoctocog alfa pegol	Not Available	Not Available	recruiting